Monday November 20, 2017 09:03

NOVO NORDISK Press Releases

Photo Release: The Royal Danish Embassy and Novo Nordisk Pharma (Thailand) Co., Ltd launch the Blueprint for Change address Diabetes challenge , aligned with national NCD targets Heathcare—14 Nov 17

On the 5th November 2017, right after the WDD event at the Vachirabenjatas Park (Suan Rot Fai Park) . Mr.Uffe Wolffhechel, the ambassador of the Royal Danish Embassy, Thailand (right) together with Mr.Mihai Irimescu, General Manager of Novo Nordisk

Photo Release: The Royal Danish Embassy and Novo Nordisk join together to support the World Diabetes Day 2017 event, held on November 5, 2017 Heathcare—18 Oct 17

Recently, Mr.Uffe Wolffhechel, Ambassador of the Royal Danish Embassy, Thailand (right) together with Mr.Mihai Irimescu, General Manager of Novo Nordisk Pharma (Thailand) Co., Ltd (left) gave a special press interview on the 2017 World Diabetes Day event

IDF and Novo Nordisk Launch First-ever Global Survey on Cardiovascular Disease Awareness among Heathcare—29 Sep 17

- Taking Diabetes to Heart is a global online survey for people with type 2 diabetes to gain important insights about their awareness of cardiovascular disease (CVD) - Globally, CVD is the most common cause of death in people with type 2 diabetes[1] -

Tresiba(R) Trial Shows that People with Type 2 Diabetes who Avoid Severe Hypoglycaemia have a Heathcare—15 Sep 17

Novo Nordisk today announced new analyses from the multinational, double-blinded DEVOTE trial showing that people with type 2 diabetes who experience severe hypoglycaemia (low blood sugar levels) are at greater risk of death. The risk was four-fold

Novo Nordisk to Present 35 Abstracts at the International Society on Thrombosis and Haemostasis Heathcare—03 Jul 17

Novo Nordisk announced today that data from 35 abstracts will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) congress from 8-13 July, in Germany. This data will be featured across posters, abstracts and oral

Tresiba(R) Demonstrated No Increased Risk Of Major Cardiovascular Events and Significant Reduction Heathcare—13 Jun 17

Novo Nordisk today announced the primary results from DEVOTE - the first randomised, double-blind, treat-to-target, event-driven trial comparing two basal insulins, Tresiba(R) (insulin degludec injection 100 U/mL) and insulin glargine U100, in adults

Fiasp(R)Black Triangle Drug, a new, ultra-fast acting mealtime insulin is available for the Heathcare—27 Mar 17

Today, Novo Nordisk announced that Fiasp(R), a new, fast-acting mealtime insulin for the treatment of diabetes in adults, has been launched in Canada, following the recent marketing authorisation from Health Canada on 6 January 2017. Fiasp(R) is insulin

NovoSeven(R) Resolved 96.5% of Bleeds When Initiated Within One Hour After Bleed Onset in People Heathcare—06 Dec 16

Novo Nordisk today announced that NovoSeven(R) (rFVIIa), a portable room temperature stable recombinant activated factor VIIa, resolved 96.5% of bleeds when initiated within one hour after onset of bleeding, demonstrating efficacy of early treatment in

Xultophy(R) Demonstrates Similar Glucose Control with Reduced Risk of Hypoglycaemia and a Superior Heathcare—02 Dec 16

Novo Nordisk today announced new phase 3b trial (DUAL VII) results with Xultophy(R) (IDegLira). Xultophy(R) is a once-daily, single injection fixed combination of a long-acting basal insulin (insulin degludec) and a glucagon-like peptide-1 (GLP-1)

Novo Nordisk Expands Programme to Reach 20,000 Children with Diabetes in Developing Heathcare—14 Nov 16

Today, Novo Nordisk announced a four-year extension of its Changing Diabetes(R) in Children programme which provides access to diabetes care and free insulin to children with type 1 diabetes in developing countries. The expansion sees five new countries

Semaglutide reduced major cardiovascular events by 26% in adults with type 2 diabetes at high Heathcare—16 Sep 16

Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly reduced the risk of the primary composite endpoint of time to first occurrence of either cardiovascular

Victoza(R) lowered the progression of kidney damage in adults with type 2 diabetes at high CV Heathcare—16 Sep 16

Novo Nordisk today announced that the progression of kidney damage was significantly lower with Victoza(R) treatment vs placebo, as measured by urinary albumin creatinine ratio, both added to standard of care in 9,340 adults with type 2 diabetes at high

Semaglutide Demonstrated Superior HbA1c Reduction vs Placebo as Add-on to Basal Insulin Alone or Heathcare—13 Sep 16

Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly improved glycaemic control compared to placebo, as add-on to basal insulin alone or in combination with

Adults with Type 2 Diabetes Treated with Xultophy(R) (IDegLira) were up to 4.5 Times More Likely to Heathcare—13 Sep 16

Novo Nordisk today presented data showing the odds of reaching fasting plasma glucose (FPG) targets without hypoglycaemia and weight gain were significantly greater for Xultophy(R) (IDegLira) compared to up-titration with insulin glargine U100 in adults

Novo Nordisk to Present 28 Abstracts at the World Federation of Hemophilia Heathcare—12 Jul 16

Novo Nordisk announced today that data from 28 abstracts will be shared at the upcoming World Federation of Hemophilia World Congress (WFH) in Orlando, Florida, from 24-28 July. The WFH Congress is the largest international meeting for the global

Victoza(R) significantly reduced the risk of major cardiovascular events and death in adults with Heathcare—14 Jun 16

Novo Nordisk today announced that Victoza(R) (liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 13% vs placebo (95% confidence

Novo Nordisk to Present 53 Abstracts at 76th Annual American Diabetes Association Scientific Heathcare—07 Jun 16

Novo Nordisk, a global leader in diabetes care, today announced that data from 53 abstracts including 8 oral presentations will be shared at the upcoming 76th annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, LA, from

Novo Nordisk mark World Haemophilia Day and unveil the 2016 HERO Research Heathcare—18 Apr 16

This material is intended for global medical media only. For journalistic assessment and preparation before publication. Today, on World Haemophilia Day, Novo Nordisk announces that the grant scheme to support and encourage research projects focused on

Semaglutide Demonstrated Superior Improvements In Glycaemic Control Vs Placebo In Adults With Type Heathcare—04 Apr 16

Findings from the first phase 3a clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that treatment with semaglutide administered once-weekly, significantly improved glycaemic control compared to

Victoza(R) (liraglutide 1.8 mg) Provided Superior HbA1c Reductions in Adults with Type 2 Diabetes Heathcare—04 Apr 16

Findings from a clinical trial comparing Victoza(R) (liraglutide 1.8 mg) and sitagliptin (100 mg), both in combination with metformin, demonstrated that switching from sitagliptin to Victoza(R) provided superior HbA1c reductions vs continuing with

New data highlight impact of post-meal hyperglycaemia on people with Heathcare—02 Dec 15

New data from four analyses[1],[2],[3],[4] demonstrate that post-meal hyperglycaemia (when blood sugar goes too high after eating) is associated with a negative physical and emotional impact on people with type 1 and type 2 diabetes[3], greater use of

New data reveal why physicians and people with type 2 diabetes uncontrolled on basal insulin are Heathcare—02 Dec 15

Results from the Perceptions of Control (POC) study showed that people with type 2 diabetes uncontrolled on basal insulin were reluctant to intensify insulin therapy due to concerns such as medication side effects, perceptions of getting sicker and not

Victoza(R) (liraglutide) provides greater glycaemic control than SGLT-2 Heathcare—02 Dec 15

New findings from a network meta-analysis show that treatment with Victoza(R) (liraglutide) provides a greater HbA1c reduction and an improved likelihood of reaching glycaemic goals compared to sodium-glucose co-transporter 2 (SGLT-2) inhibitors in

ผลวิจัยครั้งใหม่ปฏิวัติความคิดเดิมๆเกี่ยวกับการเกิดโรคเบาหวานในเมืองใหญ่ทั่วโลก สุขภาพ—16 Nov 15

จากการวิจัยครั้งใหม่ที่ทาง University College London (UCL) ได้จัดทำตามโครงการความร่วมมือ Cities Changing Diabetes นั้น พบว่า ปัจจัยทางสังคมและวัฒนธรรม ไม่ว่าจะเป็นความกดดันในเรื่องของเวลา เวลาที่ใช้ในการเดินทาง รวมถึงที่อยู่อาศัยนั้น

International Study Prompts Rethink on the Rise of Diabetes in Cities Heathcare—16 Nov 15

Pioneering new research led by University College London (UCL) for the Cities Changing Diabetes partnership shows socio-cultural factors including time pressure, commuting time and where you live play significant roles in diabetes vulnerability[1] -

Victoza(R) (liraglutide) is cost-effective vs. lixisenatide and cost-saving vs. exenatide in the Heathcare—11 Nov 15

New findings from a health economics and outcomes research (HEOR) analysis demonstrated that Victoza(R) (liraglutide) 1.2 mg is cost-effective for the treatment of type 2 diabetes in the UK market when compared to lixisenatide and is cost-saving compared

Victoza(R) (liraglutide) Provides Significantly Greater HbA1c Reduction than Lixisenatide in New Heathcare—16 Sep 15

Findings from a head-to-head trial comparing Victoza(R) (liraglutide) and lixisenatide, both in combination with metformin, demonstrated a significantly greater reduction in HbA1c of -1.83% for liraglutide vs -1.21% for lixisenatide in adults with type